OKYO

OKYO Pharma Limited · NASDAQ

Sector Health Technology
Industry Biotechnology
Website okyopharma.com
Employees(FY) 8
ISIN GG00BMFG5F62

Performance

-0.93%

+4.9%

+7.01%

-29.61%

-39.55%

YTD

-38.15%

Profile

OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic chronic pain. The company was incorporated in 2007 and is headquartered in London, the United Kingdom.

Advanced Technical Analysis

Technical Analysis of OKYO 2024-11-20

The stock indicators reflect a predominantly bearish sentiment, with the Moving Average Score at 16 indicating strong downward pressure, while the Oscillators Score of 53 suggests a neutral stance. Overall, the Technical Score of 35 reinforces the bearish outlook, signaling caution for potential investors.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of OKYO

Stock Rank

Recent News & Updates

2024-11-14 20:00
MUSQ Global Music Industry ETF and OKYO Pharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV(Accesswire)
2024-10-29 19:00
OKYO Pharma to Present at International Tear Film and Ocular Surface Society Conference(Globenewswire)
2024-10-22 19:00
OKYO Pharma Announces First Patient Dosed in the First Clinical Trial to Treat Neuropathic Corneal Pain(Globenewswire)
2024-10-16 19:27
OKYO Pharma Begins Key Phase 2 Trial for Eye Pain Drug(Yahoo Finance)
2024-10-15 19:00
OKYO Pharma Announces Start of Phase 2 Clinical Trial to Treat Patients with Neuropathic Corneal Pain(Globenewswire)
2024-09-09 19:00
OKYO Pharma Announces Chairman Acquires Shares(Globenewswire)
2024-09-04 19:00
OKYO Pharma Announces Chairman Acquires Shares(Globenewswire)
2024-08-26 19:00
OKYO Pharma Granted U.S. Patent Covering OK-101's Potential for Treating Symptoms of Dry Eye Disease(Globenewswire)
2024-08-22 21:00
OKYO Pharma CEO Interview to Air on Bloomberg TV(Globenewswire)
2024-08-22 21:00
OKYO Pharma and SolarMax Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV(Accesswire)
2024-08-22 19:00
OKYO Pharma Announces Chairman Acquires Shares(Globenewswire)
2024-08-20 19:00
OKYO Pharma Announces Chairman Acquires Shares(Globenewswire)
2024-08-15 00:13
OKYO Pharma Participates in H.C. Wainwright 4th Annual Ophthalmology Virtual Conference(Globenewswire)
2024-08-05 19:00
OKYO Pharma Granted European Patent Covering OK-101 Chemerin Analogs and Their Method of Use(Globenewswire)
2024-07-10 19:00
OKYO Pharma to Initiate Neuropathic Corneal Pain Trial for OK-101(Globenewswire)
2024-07-09 19:00
OKYO Pharma Announces Promising Categorical Data from OK-101 Phase 2 Trial in Dry Eye Disease(Globenewswire)
2024-06-25 22:29
Promising Developments from OKYO Pharma on Dry Eye Disease and Neuropathic Pain Treatment(Newsdirect)
2024-05-24 03:07
OKYO Pharma Bullish Thesis(Insidermonkey)
2024-05-07 19:00
OKYO Pharma Announces Participation in May 2024 Investor Conferences(Globenewswire)
2024-04-29 19:00
OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at the Dry Horizons Symposium, a Partner Meeting of the Association for Research in Vision and Ophthalmology (ARVO)(Globenewswire)
2024-04-08 07:00
OKYO Pharma to Reschedule Key Opinion Leader Event in Dry Eye Disease to May 2024(Globenewswire)
2024-04-01 19:00
OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at Eyecelerator 2024, a Partner Meeting of the American Society for Cataract and Refractive Surgery(Globenewswire)
2024-03-21 19:00
OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101(Globenewswire)
2024-03-20 19:00
OKYO Pharma to Host Key Opinion Leader Event to Discuss New and Comprehensive Data from Phase 2 Dry Eye Disease Trial(Globenewswire)
2024-03-19 19:00
OKYO Pharma to Release New and Comprehensive Data from Phase 2 Dry Eye Disease Trial and Host Key Opinion Leader Event(Globenewswire)
2024-02-08 18:00
OKYO Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal Pain(Globenewswire)
2024-01-30 18:00
OKYO Pharma Announces Distinguished Ophthalmologists with Expertise in the Medical and Surgical Treatment of Ocular Surface Diseases Join its Scientific Advisory Board(Globenewswire)
2024-01-07 18:00
OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Both Sign and Symptom Endpoints in its First-in-Human Phase 2 Trial of OK-101 in Patients with Dry Eye Disease(Globenewswire)
2024-01-04 20:30
OKYO Pharma to Present at the Biotech Showcase Conference in San Francisco, January 8-10, 2024(Globenewswire)
2023-12-03 18:00
OKYO Pharma Announces Last Patient Enrolled in OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease Has Completed Final Protocol Visit(Globenewswire)

Page 1 of 2

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.